RU2004116320A - Арилконденсированные азаполициклические соединения - Google Patents
Арилконденсированные азаполициклические соединения Download PDFInfo
- Publication number
- RU2004116320A RU2004116320A RU2004116320/04A RU2004116320A RU2004116320A RU 2004116320 A RU2004116320 A RU 2004116320A RU 2004116320/04 A RU2004116320/04 A RU 2004116320/04A RU 2004116320 A RU2004116320 A RU 2004116320A RU 2004116320 A RU2004116320 A RU 2004116320A
- Authority
- RU
- Russia
- Prior art keywords
- disease
- compound according
- pharmaceutically acceptable
- alkyl
- disorder
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 11
- 241000124008 Mammalia Species 0.000 claims 6
- 208000024827 Alzheimer disease Diseases 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 4
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 4
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 4
- 206010020772 Hypertension Diseases 0.000 claims 4
- 241000208125 Nicotiana Species 0.000 claims 4
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims 4
- 206010057852 Nicotine dependence Diseases 0.000 claims 4
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 4
- 208000002193 Pain Diseases 0.000 claims 4
- 208000018737 Parkinson disease Diseases 0.000 claims 4
- 208000025569 Tobacco Use disease Diseases 0.000 claims 4
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 230000009529 traumatic brain injury Effects 0.000 claims 4
- 208000028698 Cognitive impairment Diseases 0.000 claims 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 3
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 208000010877 cognitive disease Diseases 0.000 claims 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 206010003805 Autism Diseases 0.000 claims 2
- 208000020706 Autistic disease Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 208000032841 Bulimia Diseases 0.000 claims 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 208000014094 Dystonic disease Diseases 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 206010019233 Headaches Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 206010020651 Hyperkinesia Diseases 0.000 claims 2
- 208000000269 Hyperkinesis Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- 208000005314 Multi-Infarct Dementia Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 208000002389 Pouchitis Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 208000006311 Pyoderma Diseases 0.000 claims 2
- 206010039966 Senile dementia Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims 2
- 208000016620 Tourette disease Diseases 0.000 claims 2
- 208000025865 Ulcer Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 201000004810 Vascular dementia Diseases 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 208000005298 acute pain Diseases 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 208000022531 anorexia Diseases 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 206010003119 arrhythmia Diseases 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 229940125717 barbiturate Drugs 0.000 claims 2
- 229940049706 benzodiazepine Drugs 0.000 claims 2
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 claims 2
- 230000027288 circadian rhythm Effects 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 206010061428 decreased appetite Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 206010013932 dyslexia Diseases 0.000 claims 2
- 208000010118 dystonia Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000037902 enteropathy Diseases 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 231100000869 headache Toxicity 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 230000001631 hypertensive effect Effects 0.000 claims 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 2
- 208000028774 intestinal disease Diseases 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 208000014432 malignant adrenal gland pheochromocytoma Diseases 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 229960002715 nicotine Drugs 0.000 claims 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 208000019906 panic disease Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 208000022925 sleep disturbance Diseases 0.000 claims 2
- 230000001148 spastic effect Effects 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical group C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims 2
- 235000019505 tobacco product Nutrition 0.000 claims 2
- 231100000397 ulcer Toxicity 0.000 claims 2
- 230000025033 vasoconstriction Effects 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- -1 - (C 1 -C 6 ) alkyl piperazine Chemical compound 0.000 claims 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 230000003930 cognitive ability Effects 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 150000003457 sulfones Chemical class 0.000 claims 1
- 150000003462 sulfoxides Chemical class 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 0 CC1(*)C=C(C2C*CC3C2)C3=CC=C1 Chemical compound CC1(*)C=C(C2C*CC3C2)C3=CC=C1 0.000 description 5
- QHDDBWGHEWTMDV-UHFFFAOYSA-N C1Cc2nc(cccc3)c3[n]2CC1 Chemical compound C1Cc2nc(cccc3)c3[n]2CC1 QHDDBWGHEWTMDV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/02—Acyclic radicals
- C07H7/033—Uronic acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33450201P | 2001-11-30 | 2001-11-30 | |
| US60/334,502 | 2001-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2004116320A true RU2004116320A (ru) | 2005-10-10 |
Family
ID=23307510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004116320/04A RU2004116320A (ru) | 2001-11-30 | 2002-11-18 | Арилконденсированные азаполициклические соединения |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6858624B2 (enExample) |
| EP (1) | EP1451202B1 (enExample) |
| JP (1) | JP2005510568A (enExample) |
| KR (1) | KR20040063939A (enExample) |
| CN (1) | CN1596263A (enExample) |
| AR (1) | AR037596A1 (enExample) |
| AT (1) | ATE405574T1 (enExample) |
| AU (1) | AU2002365314A1 (enExample) |
| BR (1) | BR0214578A (enExample) |
| CA (1) | CA2468717A1 (enExample) |
| CO (1) | CO5570673A2 (enExample) |
| DE (1) | DE60228478D1 (enExample) |
| DO (1) | DOP2002000518A (enExample) |
| ES (1) | ES2310626T3 (enExample) |
| GT (1) | GT200200243A (enExample) |
| HN (1) | HN2002000335A (enExample) |
| IL (1) | IL161836A0 (enExample) |
| NO (1) | NO20042214L (enExample) |
| PA (1) | PA8559201A1 (enExample) |
| PE (1) | PE20030724A1 (enExample) |
| PL (1) | PL369886A1 (enExample) |
| RU (1) | RU2004116320A (enExample) |
| TW (1) | TW200300346A (enExample) |
| UY (1) | UY27554A1 (enExample) |
| WO (1) | WO2003045967A1 (enExample) |
| ZA (1) | ZA200402994B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE122008000038I1 (de) * | 1997-12-31 | 2008-11-13 | Pfizer Prod Inc | Arylkondensierte azapolycyclische derivate |
| SE521512C2 (sv) | 2001-06-25 | 2003-11-11 | Niconovum Ab | Anordning för administrering av en substans till främre delen av en individs munhåla |
| CA2511185C (en) | 2002-12-20 | 2012-09-18 | Niconovum Ab | A physically and chemically stable nicotine-containing particulate material |
| JP5694645B2 (ja) | 2006-03-16 | 2015-04-01 | ニコノヴァム エービーＮｉｃｏｎｏｖｕｍ Ａｂ | 改善された嗅ぎたばこ組成物 |
| US20090203658A1 (en) * | 2007-01-08 | 2009-08-13 | Duke University | Neuroactive steroid compositions and methods of use therefor |
| EP2198332A4 (en) * | 2007-09-06 | 2011-11-30 | 3M Innovative Properties Co | LIGHT CONDUCTOR WITH LIGHT EXTRACTION STRUCTURES FOR PROVIDING REGIONAL CONTROL OF LIGHT OUTPUT |
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| WO2022147189A1 (en) * | 2020-12-30 | 2022-07-07 | Antares Pharma, Inc. | Varenicline prodrugs |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994011030A1 (en) * | 1992-11-13 | 1994-05-26 | The Ohio State University Research Foundation | C-glycoside analogues of n-(4-hydroxyphenyl)retinamide-o-glucuronide |
| EP0937077B1 (en) | 1996-10-30 | 2006-05-17 | Pfizer Inc. | Pyridone-fused azabicyclic- or cytisine derivatives, their preparation and their use in addiction therapy |
| US6020335A (en) | 1997-02-06 | 2000-02-01 | Pfizer Inc | (N-(pyridinylmethyl)-heterocyclic)ylideneamine compounds as nicotinic acetylcholine receptor binding agents |
| US5977131A (en) | 1997-04-09 | 1999-11-02 | Pfizer Inc. | Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents |
| DE122008000038I1 (de) | 1997-12-31 | 2008-11-13 | Pfizer Prod Inc | Arylkondensierte azapolycyclische derivate |
| US6605610B1 (en) * | 1997-12-31 | 2003-08-12 | Pfizer Inc | Aryl fused azapolycyclic compounds |
| EP0955301A3 (en) | 1998-04-27 | 2001-04-18 | Pfizer Products Inc. | 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors |
| SK15952000A3 (sk) | 1998-04-29 | 2002-06-04 | Pfizer Products Inc. | Aryl-anelovaná azapolycyklická zlúčenina, jej použitie a farmaceutické kompozície na jej báze |
-
2002
- 2002-11-18 JP JP2003547416A patent/JP2005510568A/ja active Pending
- 2002-11-18 EP EP02803886A patent/EP1451202B1/en not_active Expired - Lifetime
- 2002-11-18 BR BR0214578-2A patent/BR0214578A/pt not_active IP Right Cessation
- 2002-11-18 WO PCT/IB2002/004820 patent/WO2003045967A1/en not_active Ceased
- 2002-11-18 KR KR10-2004-7008118A patent/KR20040063939A/ko not_active Abandoned
- 2002-11-18 AU AU2002365314A patent/AU2002365314A1/en not_active Abandoned
- 2002-11-18 RU RU2004116320/04A patent/RU2004116320A/ru not_active Application Discontinuation
- 2002-11-18 AT AT02803886T patent/ATE405574T1/de not_active IP Right Cessation
- 2002-11-18 DE DE60228478T patent/DE60228478D1/de not_active Expired - Fee Related
- 2002-11-18 IL IL16183602A patent/IL161836A0/xx unknown
- 2002-11-18 CA CA002468717A patent/CA2468717A1/en not_active Abandoned
- 2002-11-18 CN CNA028236289A patent/CN1596263A/zh active Pending
- 2002-11-18 PL PL02369886A patent/PL369886A1/xx not_active Application Discontinuation
- 2002-11-18 ES ES02803886T patent/ES2310626T3/es not_active Expired - Lifetime
- 2002-11-21 DO DO2002000518A patent/DOP2002000518A/es unknown
- 2002-11-25 TW TW091134186A patent/TW200300346A/zh unknown
- 2002-11-27 US US10/306,500 patent/US6858624B2/en not_active Expired - Fee Related
- 2002-11-27 HN HN2002000335A patent/HN2002000335A/es unknown
- 2002-11-27 GT GT200200243A patent/GT200200243A/es unknown
- 2002-11-28 AR ARP020104596A patent/AR037596A1/es unknown
- 2002-11-28 UY UY27554A patent/UY27554A1/es not_active Application Discontinuation
- 2002-11-28 PA PA20028559201A patent/PA8559201A1/es unknown
- 2002-11-28 PE PE2002001146A patent/PE20030724A1/es not_active Application Discontinuation
-
2004
- 2004-04-20 ZA ZA200402994A patent/ZA200402994B/en unknown
- 2004-04-26 CO CO04037673A patent/CO5570673A2/es not_active Application Discontinuation
- 2004-05-27 NO NO20042214A patent/NO20042214L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| UY27554A1 (es) | 2003-06-30 |
| DE60228478D1 (de) | 2008-10-02 |
| PA8559201A1 (es) | 2003-06-30 |
| ATE405574T1 (de) | 2008-09-15 |
| AU2002365314A1 (en) | 2003-06-10 |
| ES2310626T3 (es) | 2009-01-16 |
| JP2005510568A (ja) | 2005-04-21 |
| AR037596A1 (es) | 2004-11-17 |
| WO2003045967A1 (en) | 2003-06-05 |
| GT200200243A (es) | 2003-06-25 |
| IL161836A0 (en) | 2005-11-20 |
| NO20042214D0 (no) | 2004-05-27 |
| PE20030724A1 (es) | 2003-08-28 |
| EP1451202B1 (en) | 2008-08-20 |
| US6858624B2 (en) | 2005-02-22 |
| TW200300346A (en) | 2003-06-01 |
| CN1596263A (zh) | 2005-03-16 |
| NO20042214L (no) | 2004-05-27 |
| BR0214578A (pt) | 2004-11-03 |
| EP1451202A1 (en) | 2004-09-01 |
| ZA200402994B (en) | 2005-04-20 |
| CA2468717A1 (en) | 2003-06-05 |
| PL369886A1 (en) | 2005-05-02 |
| DOP2002000518A (es) | 2003-05-31 |
| US20030166582A1 (en) | 2003-09-04 |
| KR20040063939A (ko) | 2004-07-14 |
| CO5570673A2 (es) | 2005-10-31 |
| HN2002000335A (es) | 2003-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2621564C (en) | Pyridine derivatives and their use in the treatment of psychotic disorders | |
| KR100588391B1 (ko) | 1-페닐-4-벤질피페라진: 도파민 수용체 아류형 특이적 리간드(ｄ4) | |
| EP2379548B1 (en) | Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases | |
| KR101725696B1 (ko) | 신규한 이환형 피리딘온 | |
| RU2008138532A (ru) | Стандарты варениклина и контроль примесей | |
| JP6505023B2 (ja) | Ｃｎｓおよび他の障害を治療するための、ｐｄｅ４アイソザイムの阻害薬としてのアザベンゾイミダゾール化合物 | |
| IL263912A (en) | 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases | |
| ME00459B (me) | Aril fuzirana azapoliciklična jedinjenja | |
| RU2018130727A (ru) | Органические соединения | |
| EP3642202A1 (en) | Dihydro-pyrrolo-pyridine derivatives | |
| JP2010529135A5 (enExample) | ||
| JP2005047930A5 (enExample) | ||
| RU2004116320A (ru) | Арилконденсированные азаполициклические соединения | |
| RU2015101532A (ru) | Замещенные бициклические алкокси-пиразольные аналоги в качестве аллостерических модуляторов рецепторов mglur5 | |
| NZ590951A (en) | Cyclic nucleotide phosphodiesterases PDE10 inhibitors for treating neurological disorders | |
| EP1682549B1 (en) | Imidazo[1,2-a]pyridine anxiolytics | |
| EP2692728A1 (en) | Novel furanone derivative | |
| RU2007112675A (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1,5-a]ТРИАЗОЛО[1,5-d]БЕНЗОДИАЗЕПИНА ДЛЯ ЛЕЧЕНИЯ КОГНИТИВНЫХ РАССТРОЙСТВ | |
| CA2823935A1 (en) | Novel sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof | |
| JP2005510568A5 (enExample) | ||
| RU2005115504A (ru) | Соединения 7-фенилпиразолопиридина | |
| EP3371154A1 (en) | Heterocycle derivatives and their use for the treatment of cns disorders | |
| RU2284319C2 (ru) | Усовершенствованный способ получения 1,3-замещенных инденов | |
| EP0970054A1 (en) | 1-(isoquinolin-1-yl)-4-(1-phenylmethyl)piperazines; dopamine receptor subtype specific ligands | |
| AU2017321416B2 (en) | Hydroxynorketamine derivatives for the treatment of disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20051108 |